Part 2Dealings with medicines and medical devices
23AInterpretation
In this section, and in sections 23B and 23C, unless the context otherwise requires,—
applicant means—
- a person who makes or has made, as the case may be, an application; and
- a person on whose behalf an application is, or has been, made, as the case may be
application means an application for the consent of the Minister under section 20, or for the provisional consent of the Minister under section 23, in relation to a medicine
commencement date means the date this section and sections 23B and 23C come into force
confidential information includes—
- trade secrets; and
- information with a commercial value that would, or would be likely to, be diminished by disclosure of the information
confidential supporting information means confidential information given—
- in, or in relation to, an innovative medicine application; and
- about the medicine that is or was, as the case may be, the subject of that application
ingredient includes a chemical or biological entity
innovative medicine application means,—
- in relation to an application made after the commencement date, an application that refers to an active ingredient—
- that is an active ingredient of the medicine to which the application relates; and
- that has not, before that application is received by the Minister, been referred to in any other application (except in an application by the applicant for provisional consent for that medicine) as an active ingredient of a medicine; and
- that is an active ingredient of the medicine to which the application relates; and
- in relation to an application made before the commencement date, an application that referred to an active ingredient—
- that is or was, as the case may be, an active ingredient of the medicine to which the application related; and
- that had not, before that application was received by the Minister, been referred to in any other application (except in an application by the applicant for provisional consent for that medicine) as an active ingredient of a medicine
- that is or was, as the case may be, an active ingredient of the medicine to which the application related; and
protected period means—
- in relation to confidential supporting information, relating to an innovative medicine application, received by the Minister after the commencement date, a period commencing on the date that information is received by the Minister and ending,—
- where—on the date 5 years after the date of that notification or refusal; or
- the Minister has given notice of consent, not being provisional consent, under section 20, or refused to give consent, in relation to the medicine that is the subject of the innovative medicine application; and
- the date of publication of the notice of consent or the date of the refusal is not more than 5 years after the Minister received an application in relation to that medicine,—
- the Minister has given notice of consent, not being provisional consent, under section 20, or refused to give consent, in relation to the medicine that is the subject of the innovative medicine application; and
- in any other case, on the date 5 years after the innovative medicine application to which that information relates is or was, as the case may be, received by the Minister:
- where—on the date 5 years after the date of that notification or refusal; or
- in relation to confidential supporting information, relating to an innovative medicine application, received by the Minister not more than 5 years before the commencement date, a period commencing on the commencement date and ending,—
- where—on the date 5 years after the date of that notification or refusal; or
- the Minister has given or gives notice of consent, not being provisional consent, under section 20, or refused or refuses to give consent, in relation to the medicine that was the subject of the innovative medicine application; and
- the date of publication of the notice of consent or the date of the refusal is or was, as the case may be, not more than 5 years after the Minister received an application in relation to that medicine,—
- the Minister has given or gives notice of consent, not being provisional consent, under section 20, or refused or refuses to give consent, in relation to the medicine that was the subject of the innovative medicine application; and
- in any other case, on the date 5 years after the innovative medicine application to which that information related was received by the Minister
- where—on the date 5 years after the date of that notification or refusal; or
WTO country means a country that is a party to the Agreement establishing the World Trade Organization adopted at Marrakesh on 15 April 1994.
- a person who makes or has made, as the case may be, an application; and
Notes
- Section 23A: inserted, on , by section 2 of the Medicines Amendment Act 1994 (1994 No 128).
- Section 23A confidential information: replaced, on , by section 11 of the Agricultural Compounds and Veterinary Medicines Amendment Act 2016 (2016 No 82).
- Section 23A(a)(i)(A) protected period: replaced, on , by section 3 of the Secondary Legislation Act 2021 (2021 No 7).
- Section 23A(a)(i)(B) protected period: amended, on , by section 3 of the Secondary Legislation Act 2021 (2021 No 7).
- Section 23A(b)(i)(A) protected period: replaced, on , by section 3 of the Secondary Legislation Act 2021 (2021 No 7).
- Section 23A(b)(i)(B) protected period: amended, on , by section 3 of the Secondary Legislation Act 2021 (2021 No 7).


